US2013261071A1PendingUtilityA1
Exopolysaccharide
Est. expiryMay 4, 2027(~0.8 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 37/02A61P 29/00C07H 5/06A61P 1/10A61P 1/12A61P 1/00A61P 19/02A61P 1/04A61P 1/06C08B 37/006A23L 33/135C08B 37/00C12P 19/04A61K 31/715A23L 1/3014
38
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An isolated polysaccharide has the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] n . The polysaccharide may be from a Bifidobacterium strain NCIMB 41003. The polysaccharide exhibits immunomodulatory activity.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated polysaccharide comprising the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-] n .
2 . An isolated polysaccharide from a bacterial strain comprising the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] n .
3 . An isolated polysaccharide from a Bifidobacterium strain comprising the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] n .
4 . An isolated polysaccharide from a Bifidobacterium strain comprising the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] n .
5 . An isolated polysaccharide from Bifidobacterium strain NCIMB 41003 comprising the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] n .
6 . Use of a polysaccharide according to any of claims 1 to 5 in the preparation of a medicament for treating or preventing undesirable inflammatory activity.
7 . Use of a polysaccharide according to any of claims 1 to 5 in the preparation of a medicament for treating or preventing undesirable gastrointestinal inflammatory activity.
8 . Use according to claim 7 wherein the gastrointestinal inflammatory activity is Crohn's disease, ulcerative colitis, irritable bowel syndrome, pouchitis, post infection colitis, Clostridium difficile associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea.
9 . Use of a polysaccharide according to any of claims 1 to 5 in the preparation of a medicament for treating or preventing rheumatoid arthritis.
10 . Use of a polysaccharide according to any of claims 1 to 5 in the preparation of a medicament for treating or preventing autoimmune disorders.
11 . A pharmaceutical composition comprising a polysaccharide according to claims 1 to 5 and a pharmaceutically acceptable carrier.
12 . A foodstuff comprising a polysaccharide according to any of claims 1 to 5 .
13 . A foodstuff as claimed in claim 12 wherein the foodstuff is one or more selected from the group comprising: yogurts, cereals, beverages.
14 . An isolated polysaccharide substantially as hereinbefore described.
15 . Use of an isolated polysaccharide substantially as hereinbefore described.
16 . A pharmaceutical composition substantially as hereinbefore described.
17 . A foodstuff substantially as hereinbefore described.
18 . An isolated polysaccharide from a Bifidobacterium strain comprising the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-] n .
19 . The use of a polysaccharide as claimed in claim 18 in the preparation of a medicament for treating or preventing autoimmune disorders.Join the waitlist — get patent alerts
Track US2013261071A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.